August 28, 2026

FDA expands tirzepatide indication to cardiovascular risk reduction

SURPASS-CVOT compared tirzepatide head-to-head with dulaglutide in 13,299 participants.

MDSpire News

August 28, 2026

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

MDSpire News

August 27, 2026

TOFA may drive weight loss without reducing food intake

The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.

MDSpire News

August 19, 2026

Deciphering New Study on Heart Disease Deaths Linked to Modifiable Risk Factors

U.S. adults have made significant progress in reducing deaths from ischemic heart disease over the past three decades, researchers say nearly 9 out of 10 of these deaths are still associated with risk factors that people can often prevent or control.

Baptist Health South Florida

August 11, 2026

Midlife Vascular Risk Tied to Dementia-Free Survival

Patients with diabetes, hypertension, and current smoking in midlife lived nearly 13 fewer years without dementia than those with no vascular risk factors in a long-term US cohort study.

MDSpire News

August 07, 2026

Adrenal Tumor Patients Need the Multidisciplinary Care Roswell Park Provides

Adrenal cortical carcinomas are rare, diagnosed in only one or two people per million annually, but are also more likely to be found at a later state because they are largely asymptomatic.

Roswell Park Comprehensive Cancer Center

July 29, 2026

Can Statin Muscle Risk Be Predicted?

Researchers developed and externally validated a prediction model estimating 1-, 5-, and 10-year risks of serious muscle disorders among patients potentially eligible for statin therapy.

MDSpire News

July 16, 2026

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

MDSpire News

July 09, 2026

Prolonged Sleep Restriction May Increase Body Weight

In a pooled analysis of two randomized crossover trials, reducing nightly sleep by about 1.5 hours for 6 weeks was associated with modest increases in body weight and waist circumference without measurable changes in body composition.

MDSpire News

July 06, 2026

ACP Ranks Obesity Drug Options

A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.

MDSpire News